The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Living With HIV: Watch Aaron's Story
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Ready to Launch: ADAPT Study Looks at Intermittent Dosing of PrEP

June 7, 2011

Investigators at the HIV Prevention Trials Network (HPTN) Annual Meeting Monday received an update on a study looking to ease the pill burden on those wishing to benefit from pre-exposure prophylaxis (PrEP).

Inspired by studies of non-human primates over the past seven years at the Centers for Disease Control and Prevention, the HPTN 067 "ADAPT" study (Alternate Dosing to Augment PrEP Tablet-taking) is a behavioral study looking at how adherence can be improved by lowering the frequency and potency of each dose, while achieving "comparable" efficacy in preventing HIV infection.

The primate studies, "... Encourage us that daily doses might not be necessary, and easier dosing that is better adaptable to people may be possible," said Bob Grant, MD, of the Gladstone Institute of Virology and Immunology in San Francisco, who presented on the study.  The idea of adapting PrEP regimens to the patients' needs was well-received by the audience, and Grant said it was a key concept to improving adherence, "especially in terms of  people whose lives are not defined by a disease they don't have."

View Full Article

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Visit Project Inform's website to find out more about their activities, publications and services.
See Also
More News and Research on HIV Medications for HIV Prevention

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: